Compare GDTC & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDTC | COSM |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | Singapore | United States |
| Employees | 34 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 18.9M |
| IPO Year | 2021 | 2009 |
| Metric | GDTC | COSM |
|---|---|---|
| Price | $1.00 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 454.2K | ★ 709.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $54,426,402.00 |
| Revenue This Year | $5.37 | $20.69 |
| Revenue Next Year | N/A | $53.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.97 |
| 52 Week Low | $0.73 | $0.28 |
| 52 Week High | $3.68 | $1.32 |
| Indicator | GDTC | COSM |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 40.51 |
| Support Level | $0.87 | $0.35 |
| Resistance Level | $1.25 | $0.50 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 57.11 | 40.29 |
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.